| Literature DB >> 29147738 |
Marek Wojnicki1, Magdalena Luty-Błocho2, Magdalena Kotańska3, Magdalena Wytrwal4, Tomasz Tokarski4, Anna Krupa5, Marcin Kołaczkowski6, Adam Bucki6, Marcin Kobielusz7.
Abstract
In this study, the protocol of a single-step L-cysteine functionalizedEntities:
Keywords: Drug carrier; Functionalization; L-cysteine; Silver nanoparticles; Synthesis; Toxicity
Mesh:
Substances:
Year: 2017 PMID: 29147738 PMCID: PMC5778179 DOI: 10.1007/s00210-017-1440-x
Source DB: PubMed Journal: Naunyn Schmiedebergs Arch Pharmacol ISSN: 0028-1298 Impact factor: 3.000
Fig. 1Survey scan performed with X-ray photoelectron spectroscopy of AgNPs (a). XPS spectra with fitted lines C 1s (b), Ag 3d (c), and S 2p (d)
Fig. 2a UV-Vis spectrum of obtained AgNPs. b Determination of absorption coefficient
Fig. 3Particle size distribution determined using a DLS method and b HR-TEM image analysis method
Fig. 4HR-TEM analysis (a) and selection of polycrystal structure (b) FFT analysis of single crystal (c)
Fig. 5XRD pattern of obtained AgNPs
Fig. 6Fluorescence of AgNPs functionalized with l-cysteine
Fig. 7Body weight changes. a Comparison of control group to tested group after intraperitoneal administration. b Comparison of control group to tested group after intragastric administration. Mean ± SEM, n = 6. Statistical significance: *p < 0.05 (two-way ANOVA)
AgNP biodistribution in selected organs in percentage of given dose
| Brain | Kidneys | Liver | Blood |
|---|---|---|---|
| After P.O administration | |||
| 1.82 × 10−2 ± 5.79 × 10−3 | 1.55 × 10−2 ± 2.21 × 10−3 | 6.53 × 10−2 ± 2.87 × 10−2 | 4.16 × 10−2 ± 1.51 × 10−2 |
| After I.P administration | |||
| 3.59 × 10−2 ± 1.52 × 10−3 | 2.98 × 10−1 ± 6.24 × 10−2 | 2.93 ± 4.31 × 10−1 | 9.45 × 10−2 ± 5.46 × 10−2 |